The KLHDC2 antibody targets the Kelch domain-containing protein 2 (KLHDC2), a member of the Kelch superfamily characterized by conserved β-propeller Kelch repeat motifs. KLHDC2 is implicated in protein-protein interactions and is thought to act as a substrate receptor for CUL2-based E3 ubiquitin ligase complexes, facilitating substrate recognition and subsequent ubiquitination for proteasomal degradation. While its precise biological roles remain under investigation, KLHDC2 has been linked to cellular processes such as cell cycle regulation, apoptosis, and stress response. Dysregulation of KLHDC2 expression has been observed in certain cancers, suggesting potential involvement in tumorigenesis or tumor suppression, though mechanistic insights are limited.
KLHDC2 antibodies are primarily utilized in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These tools aid in elucidating KLHDC2’s function in physiological and pathological contexts. Commercial antibodies are typically validated for specificity, often through knockout cell lines or siRNA knockdown. Emerging studies explore KLHDC2’s role in diseases beyond cancer, including neurological disorders, highlighting its broader relevance. However, standardized protocols and comprehensive functional data remain scarce, underscoring the need for further characterization. KLHDC2 antibodies thus serve as critical reagents for advancing understanding of its molecular mechanisms and therapeutic potential.